The combination of the first-ever biologic approved for atopic dermatitis and the massive size of the indication's market has raised interest in the disease to new heights, including during the American Academy of Dermatology (AAD) meeting from Feb. 16 to 19 in San Diego.
"The prevalence of the disease seems to be emerging and much higher than we appreciated," Emma Guttman, a dermatologist and a professor at the Icahn School of Medicine at Mount
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?